Additional file 1: Table S1. of Defining cognitive impairment in people-living-with-HIV: the POPPY study

Cognitive tests administered by cognitive domain. (DOCX 13 kb

Proportion (95% CI) receiving RHZ-based empiric therapy (a) and proportion (95%CI) with MDR-TB (b) in different countries and study regions.

<p>The intraregional differences in the use of RHZ-based empiric anti-TB treatment are shown in relation to the observed MDR-TB prevalence.</p

Factors associated with MDR-TB in multivariable logistic regression analysis.

<p>Factors associated with MDR-TB in multivariable logistic regression analysis.</p

Characteristics at HIV diagnosis of late presenters and late presenters with advanced disease: COHERE 2000–2011.

<p>Late presentation: diagnosed with HIV with a CD4 count below 350/mm³ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm³or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.</p>a<p>Delayed entry into care: ≥3 mo between HIV diagnosis and first clinic visit, in those patients where both dates were recorded (<i>n</i> = 34,561). Baseline was defined as the earliest of HIV test, first study visit, or cohort enrolment. “Other” regions included Central/Southern America (<i>n</i> = 4,277) and Asia (<i>n</i> = 1,005). “Other” HIV male and female transmission groups included 5,350 (84.8%) and 2,046 (70.8%) patients with unknown HIV-exposure group, respectively, likely to include a number of IDUs, MSMs, and heterosexuals.</p><p>IQR, interquartile range.</p

(A–D) Progression to new AIDS/death: role of late presentation or late presentation with advanced disease: COHERE 2000–2011.

<p>(A) Southern Europe. (B) Central Europe. (C) Northern Europe. (D) Eastern Europe. LP, diagnosed with HIV with a CD4 count below 350/mm³ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Presentation with advanced disease (AD): diagnosed with HIV with a CD4 count below 200/mm³ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis.</p

Sensitivity analyses showing the proportion of late presenters or late presenters with advanced disease using different inclusion criteria for CD4 count at HIV diagnosis: COHERE 2000–2011.

<p>Late presentation: diagnosed with HIV with a CD4 count below 350/mm³ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm³or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.</p>a<p>Corresponds to main analyses presented in <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001510#s4" target="_blank">Results</a>.</p><p>AD, advanced disease; LP, late presenter.</p

Changes over time in late presentation and CD4 count at HIV diagnosis: COHERE 2000–2011.

<p>Late presentation: diagnosed with HIV with a CD4 count below 350/mm³ or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm³or an AIDS defining event, regardless of CD4 cell count, in the 6 mo following HIV diagnosis.</p

(A–D) Changes in late presentation over calendar time; stratified by HIV exposure group: COHERE 2000–2011.

<p>(A) Southern Europe. (B) Central Europe. (C) Northern Europe. (D) Eastern Europe. All models adjusted for age, delayed entry into care (≥3 mo) after HIV diagnosis, region of origin, European region of care, and HIV mode of infection. F, female; Het, heterosexual; M, male.</p

Number and percentage of AIDS/deaths and adjusted incidence rate ratios of AIDS/death after HIV diagnosis in COHERE 2000–2011; late presenters versus non late presenters stratified by European region of care and time since presentation.

<p>Adjusted additionally for age, region of origin, delayed entry into care (≥3 mo between HIV diagnosis and first clinic visit), and HIV-exposure group. Late presentation: presenting for care with a CD4 count below 350/mm³ or presenting with an AIDS defining event regardless of the CD4 count, in the 6 mo following presentation. Advanced disease: presenting for care with a CD4 count below 200/mm³or presenting with an AIDS defining event, regardless of CD4 cell count, in the 6 mo following presentation.</p>a<p>Figures are <i>n</i> (%) of clinical events (AIDS/deaths) in late presenters or late presenters with advanced disease.</p